-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $280

Benzinga·08/04/2026 10:30:58
Listen to the news
Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $252 to $280.